Eli Lilly Acquires AtaiBeckley, Enters Psychedelic Drug Market

By EC Assets · Published 16 July 2026

Eli Lilly is expanding its pharmaceutical portfolio by acquiring psychedelics maker AtaiBeckley. The agreement is valued at up to $3.8 billion. This move positions Lilly within the evolving psychedelic drug sector. Eli Lilly will buy AtaiBeckley for $2.8 billion. Experimental treatments are gaining traction in this area. This acquisition represents Lilly's entry into the psychedelic drug market. The market capitalization of tokenized stocks has recently reached $2.3 billion. Certain companies are pursuing cheaper AI models. Nvidia, backed Fireworks, for instance, achieved a $17.5 billion valuation. This article is intended for informational purposes only. It does not constitute investment advice.